Caiqin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Caiqin Zhang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Changhong Shi
Division of Cancer Biology, Laboratory Animal Center, Air Force Medical University, Xi’an, China
2 shared publications Bing Bai
Laboratory Animal Center, The Fourth Military Medical University 1 Division of Cancer Biology Xi'an, Shaanxi 710032
1 shared publication- Dengxu Tan
Division of Cancer Biology
1 shared publication Han Meng
Laboratory Animal Center, The Fourth Military Medical University 1 Division of Cancer Biology Xi'an, Shaanxi 710032
1 shared publication- He Zhang
Division of Cancer Biology
1 shared publication Jiaze An
Department of Hepatobiliary and Pancreaticosplenic Surgery
1 shared publication
Latest Publications
- Open Access
- 1 November 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (11)
Characteristics of Japanese encephalitis virus infection in NCG-hSTAT2+/+ mice: a novel model for studying neurological symptoms and immune response
Japanese encephalitis virus (JEV), a leading cause of viral encephalitis in Asia and the Western Pacific, is regulated by type I interferon (IFN) signaling pathway, in which STAT2 is critical. However, the exact role of STAT2 in JEV-mediated IFN evasion remains unclear. Existing murine models of JEV infection predominantly employ high viral titers to induce encephalitis and primarily use immunocompetent or IFN receptor-deficient mice, limiting their use to study the IFN evasion mechanisms of JEV. To address this, we developed a humanized STAT2 mouse model (NCG-hSTAT2+/+) and infected it with 10³ PFU of JEV-p3. These mice exhibited severe encephalitis resembling clinical human infections, characterized by elevated viral load, and increased proinflammatory cytokines. Especially, they presented typical neurological symptoms, such as activated astrocytes and distinct neuropathological changes. This suggests that NCG-hSTAT2+/+ mice exhibit higher susceptibility to JEV and more-severe neurological symptoms, which is consistent with the clinical manifestations observed in human patients. This mouse model significantly advances the study of JEV pathogenesis, the therapeutic evaluation of this infection and the role human STAT2 has in neuroinvasion and immune evasion.
- 1 November 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (11)
Open AccessCharacteristics of Japanese encephalitis virus infection in NCG-hSTAT2+/+ mice: a novel model for studying neurological symptoms and immune response
Japanese encephalitis virus (JEV), a leading cause of viral encephalitis in Asia and the Western Pacific, is regulated by type I interferon (IFN) signaling pathway, in which STAT2 is critical. However, the exact role of STAT2 in JEV-mediated IFN evasion remains unclear. Existing murine models of JEV infection predominantly employ high viral titers to induce encephalitis and primarily use immunocompetent or IFN receptor-deficient mice, limiting their use to study the IFN evasion mechanisms of JEV. To address this, we developed a humanized STAT2 mouse model (NCG-hSTAT2+/+) and infected it with 10³ PFU of JEV-p3. These mice exhibited severe encephalitis resembling clinical human infections, characterized by elevated viral load, and increased proinflammatory cytokines. Especially, they presented typical neurological symptoms, such as activated astrocytes and distinct neuropathological changes. This suggests that NCG-hSTAT2+/+ mice exhibit higher susceptibility to JEV and more-severe neurological symptoms, which is consistent with the clinical manifestations observed in human patients. This mouse model significantly advances the study of JEV pathogenesis, the therapeutic evaluation of this infection and the role human STAT2 has in neuroinvasion and immune evasion.
- Open Access
- 5 August 2022
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 2022 (1) , 6596702
The Application of [68Ga]‐Labeled FAPI‐04 PET/CT for Targeting and Early Detection of Pancreatic Carcinoma in Patient‐Derived Orthotopic Xenograft Models
[18F]FDG as a probe of PET/CT is a radiolabeled glucose analogue taken up by most cells, but its batch activity is limited. [68Ga]FAPI‐04 is a promising alternative based on a fibroblast activation protein‐specific inhibitor (FAPI) labeled with radiotracer FAP. Here, a series of databases suggested that FAP expression was significantly different in pancreatic cancer compared to normal tissue. The FAP‐positive fibroblasts were evaluated around the tumor cells and the stroma. A patient‐derived orthotopic xenograft (PDOX) model of pancreatic adenocarcinoma (PDAC) exhibits significantly higher quantitative uptake of [68Ga]FAPI‐04 (P < 0.05) than [18F]FDG PET/CT in various organs. Because of relatively high (T/M) ratios, the [68Ga]FAPI‐04 is excellent for B‐mode ultrasound, NIRF, and PET/CT. Thus, [68Ga]FAPI‐04 PET displayed a better tumor specificity and can be a potential application for the early detection of pancreatic cancer.
- 5 August 2022
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 2022 (1) , 6596702
Open AccessThe Application of [68Ga]‐Labeled FAPI‐04 PET/CT for Targeting and Early Detection of Pancreatic Carcinoma in Patient‐Derived Orthotopic Xenograft Models
[18F]FDG as a probe of PET/CT is a radiolabeled glucose analogue taken up by most cells, but its batch activity is limited. [68Ga]FAPI‐04 is a promising alternative based on a fibroblast activation protein‐specific inhibitor (FAPI) labeled with radiotracer FAP. Here, a series of databases suggested that FAP expression was significantly different in pancreatic cancer compared to normal tissue. The FAP‐positive fibroblasts were evaluated around the tumor cells and the stroma. A patient‐derived orthotopic xenograft (PDOX) model of pancreatic adenocarcinoma (PDAC) exhibits significantly higher quantitative uptake of [68Ga]FAPI‐04 (P < 0.05) than [18F]FDG PET/CT in various organs. Because of relatively high (T/M) ratios, the [68Ga]FAPI‐04 is excellent for B‐mode ultrasound, NIRF, and PET/CT. Thus, [68Ga]FAPI‐04 PET displayed a better tumor specificity and can be a potential application for the early detection of pancreatic cancer.